PMID- 32536573
OWN - NLM
STAT- MEDLINE
DCOM- 20220201
LR  - 20220201
IS  - 2588-9311 (Electronic)
IS  - 2588-9311 (Linking)
VI  - 4
IP  - 4
DP  - 2021 Aug
TI  - Magnetic Resonance-guided Stereotactic Radiotherapy for Localized Prostate 
      Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 
      Study.
PG  - 628-634
LID - S2588-9311(20)30061-4 [pii]
LID - 10.1016/j.euo.2020.05.007 [doi]
AB  - BACKGROUND: The recent introduction of magnetic resonance-guided radiation 
      therapy (MRgRT) has allowed improved treatment planning and delivery of 
      stereotactic body radiotherapy (SBRT) in prostate cancer (PC). The health-related 
      quality of life (HRQoL) outcomes using this novel approach are important in 
      shared decision making for patients. OBJECTIVE: To report HRQoL using both 
      patient- and clinician-reported outcomes at 1 yr following stereotactic MRgRT for 
      patients with localized PC. DESIGN, SETTING, AND PARTICIPANTS: A prospective 
      phase 2 trial included 101 patients with localized PC. INTERVENTION: All patients 
      received 36.25Gy in five fractions of MRgRT delivered within 2 wk. OUTCOME 
      MEASUREMENTS AND STATISTICAL ANALYSIS: HRQoL was prospectively assessed at 
      baseline, at the last fraction, at 6 wk, and at 3, 6, 9, and 12 mo after 
      treatment, by patient-reported outcome measures using European Organization for 
      Research and Treatment of Cancer QLQ-C30 and QLQ-PR25 questionnaires, and 
      International Prostate Symptom Score. At the same time points, clinicians 
      reported on symptomatic adverse events (AEs). Effect sizes for changes in HRQoL 
      were calculated with repeated measures analysis of variance. RESULTS AND 
      LIMITATIONS: Availability of HRQoL data exceeded 95% at all study time points. 
      From both questionnaires and the recorded AEs, the largest treatment effects on 
      urinary and bowel symptoms were recorded in the first 6 wk of follow-up. 
      Thereafter, all symptoms decreased and returned to baseline values at 12 mo. No 
      grade >/=3 toxicity was reported. No patient reported any relevant limitation due 
      to urinary symptoms, and only 2.2% of patients reported a relevant impact on 
      daily activities due to bowel problems at 1 yr. The majority of patients had 
      intermediate- or high-risk PC for which androgen deprivation therapy (83.2%) was 
      prescribed, thereby precluding study of MRgRT on sexual function. Longer 
      follow-up is awaited in order to evaluate the oncological outcome. CONCLUSIONS: 
      Delivery of MRgRT for SBRT resulted in low toxicity at 1 yr. PATIENT SUMMARY: All 
      patients completed magnetic resonance-guided radiation therapy, which was well 
      tolerated with only transient early urinary and bowel symptoms, which resolved 1 
      yr after treatment, as confirmed by patient-reported outcome measures.
CI  - Copyright (c) 2020 European Association of Urology. Published by Elsevier B.V. All 
      rights reserved.
FAU - Tetar, Shyama U
AU  - Tetar SU
AD  - Department of Radiation Oncology, Amsterdam UMC, location VUmc, Amsterdam, The 
      Netherlands.
FAU - Bruynzeel, Anna M E
AU  - Bruynzeel AME
AD  - Department of Radiation Oncology, Amsterdam UMC, location VUmc, Amsterdam, The 
      Netherlands.
FAU - Oei, Swie S
AU  - Oei SS
AD  - Department of Radiation Oncology, Amsterdam UMC, location VUmc, Amsterdam, The 
      Netherlands.
FAU - Senan, Suresh
AU  - Senan S
AD  - Department of Radiation Oncology, Amsterdam UMC, location VUmc, Amsterdam, The 
      Netherlands.
FAU - Fraikin, Tamara
AU  - Fraikin T
AD  - Department of Radiation Oncology, Amsterdam UMC, location VUmc, Amsterdam, The 
      Netherlands.
FAU - Slotman, Berend J
AU  - Slotman BJ
AD  - Department of Radiation Oncology, Amsterdam UMC, location VUmc, Amsterdam, The 
      Netherlands.
FAU - Moorselaar, R Jeroen A van
AU  - Moorselaar RJAV
AD  - Department of Urology, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands. 
      Electronic address: rja.vanmoorselaar@amsterdamumc.nl.
FAU - Lagerwaard, Frank J
AU  - Lagerwaard FJ
AD  - Department of Radiation Oncology, Amsterdam UMC, location VUmc, Amsterdam, The 
      Netherlands.
LA  - eng
SI  - ClinicalTrials.gov/NCT03961321
PT  - Clinical Trial, Phase II
PT  - Journal Article
DEP - 20200612
PL  - Netherlands
TA  - Eur Urol Oncol
JT  - European urology oncology
JID - 101724904
RN  - 0 (Androgen Antagonists)
SB  - IM
MH  - *Androgen Antagonists
MH  - Humans
MH  - Magnetic Resonance Spectroscopy
MH  - Male
MH  - Patient Reported Outcome Measures
MH  - Prospective Studies
MH  - *Prostatic Neoplasms/radiotherapy
MH  - Quality of Life
OTO - NOTNLM
OT  - Health-related quality of life
OT  - Magnetic resonance-guided
OT  - Online plan adaptation
OT  - Patient-reported outcomes
OT  - Prostate cancer
OT  - Stereotactic body radiotherapy
EDAT- 2020/06/17 06:00
MHDA- 2022/02/02 06:00
CRDT- 2020/06/16 06:00
PHST- 2020/03/17 00:00 [received]
PHST- 2020/05/07 00:00 [revised]
PHST- 2020/05/15 00:00 [accepted]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2022/02/02 06:00 [medline]
PHST- 2020/06/16 06:00 [entrez]
AID - S2588-9311(20)30061-4 [pii]
AID - 10.1016/j.euo.2020.05.007 [doi]
PST - ppublish
SO  - Eur Urol Oncol. 2021 Aug;4(4):628-634. doi: 10.1016/j.euo.2020.05.007. Epub 2020 
      Jun 12.